CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 44 enrolled
Drug / intervention
Tobacco product administration and assessment, own brand cigarettes +4 moreother
Likely dose
Tobacco product administration and assessment, ECIG 30 Watts, 0 mg/ml nicotinefrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04332926
NCT04332926N/ACompleted
CompareCT.gov

Effects of E-Cigarette Nicotine Content in Smokers (Nicotine Flux Study)

Virginia Commonwealth University·interventional·Posted Apr 3, 2020·Updated Feb 13, 2025

In Brief

A clinical study evaluating Tobacco product administration and assessment, own brand cigarettes, Tobacco product administration and assessment, ECIG 30 Watts, 0 mg/ml nicotine, and 3 other interventions for Electronic Cigarette Use. Completed, enrolled 44 participants across 1 site.

Detailed Summary

This study aims to better understand how e-cigarettes (ECIG) nicotine flux impacts several behavioral economic measures of abuse liability.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsElectronic Cigarette Use
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedApr 3, 2020
Enrollment StartJan 5, 2021
Primary CompletionJun 1, 2023
Study CompletionSep 8, 2023
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 6.2 years ago

Interventions

Tobacco product administration and assessment, own brand cigarettesother

4 sample puffs, followed by a 60 minute rest period, hypothetical drug purchase tasks, followed by progressive ratio tasks (single product and two products, with 60 minute rest in between) where participants work to earn puffs of tobacco products; preceded and followed by physiological and subjective assessment

Tobacco product administration and assessment, ECIG 30 Watts, 0 mg/ml nicotineother

4 sample puffs, followed by a 60 minute rest period, hypothetical drug purchase tasks, followed by progressive ratio tasks (single product and two products, with 60 minute rest in between) where participants work to earn puffs of tobacco products; preceded and followed by physiological and subjective assessment

Tobacco product administration and assessment, ECIG 30 Watts, 8 mg/ml nicotineother

4 sample puffs, followed by a 60 minute rest period, hypothetical drug purchase tasks, followed by progressive ratio tasks (single product and two products, with 60 minute rest in between) where participants work to earn puffs of tobacco products; preceded and followed by physiological and subjective assessment

Tobacco product administration and assessment, ECIG 30 Watts, 15 mg/ml nicotineother

4 sample puffs, followed by a 60 minute rest period, hypothetical drug purchase tasks, followed by progressive ratio tasks (single product and two products, with 60 minute rest in between) where participants work to earn puffs of tobacco products; preceded and followed by physiological and subjective assessment

Tobacco product administration and assessment, ECIG 30 Watts, 30 mg/ml nicotineother

4 sample puffs, followed by a 60 minute rest period, hypothetical drug purchase tasks, followed by progressive ratio tasks (single product and two products, with 60 minute rest in between) where participants work to earn puffs of tobacco products; preceded and followed by physiological and subjective assessment